By Claudio D’Angelo, Founder and Managing Director of Spex Capital
At the close of April, Spex Capital turned one.
In celebrating our first birthday, I wanted to take the opportunity to reflect and appreciate on what has been a whirlwind of a year.
Last year, as the world was coming to grips with Covid, we launched Spex Capital with the mission of helping digital healthcare and med-tech start-ups deliver breakthroughs in healthcare systems. Since then, the world has returned to some level of normalcy, yet the growth in the health-tech sector and the digital health boom have shown no signs of tapering.
Looking back on the past year, it’s incredible just how quickly it passed by and how much we have been able to achieve in such a short timeframe.
A company is only as good as the people that make it up.
Spex Capital kicked off with a strong team of twelve in place, made up of five investment team members and seven senior advisors. By Christmas, our team had grown to seventeen members and we’ve now hit the twenty mark with a team of eleven investors, seven advisors and two venture partners. Our diversified and multidisciplinary investment team is a source of pride and our point of strength: bridging the gap between the financial and medical sectors ensuring we are able to select winners and provide the best possible support for our companies.
However, the support doesn’t limit itself to team members, but to the network of partners we’ve built.
Over the course of the year, we’ve renewed and expanded on our world-class ecosystem via partnerships and relationships with accelerators and incubators, universities, hospitals, embassies, chambers of commerce, trade bodies, payors, and healthcare systems across all continents to source the highest quality technologies worldwide.
Most notably, we joined forces with MedCity, the London-based life sciences cluster organisation, through an exclusive, long-term partnership which saw us launch a joint investment call in late 2021. The call, which invited early-stage companies seeking seed and Series A to secure up to €5,000,000 of investment, attracted over 200 applications. Following a thorough review, an initial selection of 112 companies brought us to shortlisting and interviewing 34 target companies, and are now in the process of conducting extended due diligence with our final shortlist.
Looking to the future, Spex Capital has its sight set on growing our portfolio via our maiden fund and further expanding our network. Our drive translates into an ever-expanding team dedicated to supporting the incredible pool of talent with unexpressed potential in digital health and med-tech.
The digital healthcare revolution has just begun. Bring on year two.
